Advertisement
Australia markets closed
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • AUD/USD

    0.6624
    -0.0013 (-0.20%)
     
  • OIL

    78.09
    -0.53 (-0.67%)
     
  • GOLD

    2,326.40
    +8.40 (+0.36%)
     
  • Bitcoin AUD

    101,119.73
    -827.45 (-0.81%)
     
  • CMC Crypto 200

    1,426.68
    +8.81 (+0.62%)
     
  • AUD/EUR

    0.6174
    +0.0002 (+0.02%)
     
  • AUD/NZD

    1.0784
    +0.0032 (+0.29%)
     
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NASDAQ

    19,576.92
    +111.74 (+0.57%)
     
  • FTSE

    8,163.67
    0.00 (0.00%)
     
  • Dow Jones

    38,647.10
    -65.11 (-0.17%)
     
  • DAX

    18,265.68
    -365.18 (-1.96%)
     
  • Hang Seng

    18,006.26
    -106.37 (-0.59%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

ImpediMed First Half 2023 Earnings: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

ImpediMed (ASX:IPD) First Half 2023 Results

Key Financial Results

  • Revenue: AU$5.66m (up 8.8% from 1H 2022).

  • Net loss: AU$10.8m (loss widened by 21% from 1H 2022).

  • AU$0.01 loss per share (further deteriorated from AU$0.006 loss in 1H 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

ImpediMed Earnings Insights

Looking ahead, revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia.

Performance of the Australian Medical Equipment industry.

The company's shares are down 5.1% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for ImpediMed that you should be aware of.

ADVERTISEMENT

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here